Steven Wiley's questions to Abeona Therapeutics Inc (ABEO) leadership • Q2 2025
Question
Tully on for Steven Wiley of Stifel questioned if the initial QTCs are a good proxy for future patient numbers, whether the two active centers are sufficient to meet 2025 guidance, and if the Q2 SG&A spend is a reliable run-rate.
Answer
CEO Vishwas Seshadri and CCO Madhav Vasanthavada confirmed the two active QTCs have identified enough patients (~50) to support the 2025 guidance of 10-14 patients and build a strong funnel for 2026. CFO Joseph Vazzano clarified that while the overall operating burn trend is indicative, the Q2 SG&A figure itself will fluctuate quarterly due to the accounting mix of production and engineering costs between R&D, COGS, and SG&A.